NEW YORK, NY / ACCESSWIRE / April 23, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.
Stamps.com Inc. (STMP)
Class Period: May 3, 2017 - February 21, 2019
Lead Plaintiff Deadline : April 29, 2019
Join the action: https://www.zlk.com/pslra-1/stamps-com-inc-loss-form?prid=1230&wire=1
The lawsuit alleges: Stamps.com Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's financial results depended on the manipulation of a USPS program that cost USPS an estimated $235 million per year; and (ii) as a result, the Company's business was unsustainable and its financial results were highly misleading.
To learn more about the Stamps.com Inc. class action contact email@example.com.
Bridgepoint Education Inc. (BPI)
Class Period: March 8, 2016 - March 7, 2019
Lead Plaintiff Deadline : May 10, 2019
Join the action: https://www.zlk.com/pslra-1/bridgepoint-education-inc-loss-form?prid=1230&wire=1
The lawsuit alleges: Bridgepoint Education Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) Bridgepoint's processes for recording revenue for its FTG program were inaccurate; (ii) Bridgepoint maintained deficient internal controls; (iii) due to the foregoing deficiencies, Bridgepoint was prone to and did commit material accounting errors related to revenue, provision for bad debts, accounts receivable and deferred revenue, which resulted in the overstatement of revenue and expenses; and (iv) as a result, Bridgepoint's public statements were materially false and misleading at all relevant times.
To learn more about the Bridgepoint Education Inc. class action contact firstname.lastname@example.org.
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Class Period: November 14, 2016 - February 28, 2019
Lead Plaintiff Deadline : May 13, 2019
Join the action: https://www.zlk.com/pslra-1/corbus-pharmaceutical-holdings-inc-loss-form?prid=1230&wire=1
The lawsuit alleges that, during the class period, Corbus Pharmaceuticals Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Corbus improperly changed the primary efficacy endpoint for the clinical study of its drug candidate, Lenabasum, after the results were unblinded to Corbus; (2) Corbus reported a one-sided p value, not the traditional two-sided p value normally reported in clinical trials, in an effort to conceal the fact that the study results did not have statistical significance; and (3) as a result, Corbus' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To learn more about the Corbus Pharmaceuticals Holdings, Inc. class action contact email@example.com.
You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: